Î’-lactam-associated neutropenia: Difference between revisions

From IDWiki
Î’-lactam-associated neutropenia
(Created page with "{{DISPLAYTITLE:β-lactam-associated neutropenia}} == Background == * Adverse reaction to β-lactam antibiotics occurring in about 1 to 10% of prolonged courses * Higher risk with penicillin G, nafcillin, oxacillin, piperacillin-tazobactam, ceftriaxone, and ceftaroline * Risk increases with cumulative exposure * Mechanism is unclear; may be some combination of a direct toxic effect or an Hypersensitivity reaction|immune-mediated...")
 
 
Line 3: Line 3:
 
== Background ==
 
== Background ==
   
−
* Adverse reaction to [[Β-lactams|β-lactam antibiotics]] occurring in about 1 to 10% of prolonged courses
+
* Adverse reaction to [[Β-lactams|β-lactam antibiotics]] occurring in about 10% of courses longer than 2 weeks
 
* Higher risk with [[penicillin G]], [[nafcillin]], [[oxacillin]], [[piperacillin-tazobactam]], [[ceftriaxone]], and [[ceftaroline]]
 
* Higher risk with [[penicillin G]], [[nafcillin]], [[oxacillin]], [[piperacillin-tazobactam]], [[ceftriaxone]], and [[ceftaroline]]
 
* Risk increases with cumulative exposure
 
* Risk increases with cumulative exposure
Line 11: Line 11:
   
 
* [[Neutropenia]]
 
* [[Neutropenia]]
  +
* Usually presents after 2 to 3 weeks of parenteral antibiotics
  +
* Rash in 25-50% of cases
  +
* May have associated [[eosinophilia]] or [[thrombocytopenia]]
 
* Can progress to [[agranulocytosis]]
 
* Can progress to [[agranulocytosis]]
   
 
== Management ==
 
== Management ==
   
−
* Stop the offending agent
+
* Consider stopping the offending antibiotic if ANC falls below 1
 
* Other β-lactam antibiotics are probably still safe to use
 
* Other β-lactam antibiotics are probably still safe to use
   

Latest revision as of 23:20, 23 July 2022


Background

Clinical Manifestations

Management

  • Consider stopping the offending antibiotic if ANC falls below 1
  • Other β-lactam antibiotics are probably still safe to use

Further Reading

  • A Review of β-Lactam-Associated Neutropenia and Implications for Cross-reactivity. Ann Pharmacother. 2021;55(8):1037-1049. doi: 10.1177/1060028020975646